- Home
- FTW vs AUTL Comparison
FTW vs AUTL Comparison
Compare FTW & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTW | AUTL |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.6M | 335.4M |
| IPO Year | 2026 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FTW | AUTL |
|---|---|---|
| Price | $10.21 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $15.00 | $8.75 |
| AVG Volume (30 Days) | 51.8K | ★ 2.1M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | ★ 13.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $32.44 | $98.68 |
| Revenue Next Year | $3.93 | $28.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.46 | $1.18 |
| 52 Week High | $17.20 | $2.58 |
Technical Indicators
Market Signals| Indicator | FTW | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 29.87 |
| Support Level | $9.99 | $1.18 |
| Resistance Level | $10.54 | $1.71 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 44.50 | 17.39 |
Price Performance
Historical ComparisonAbout FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
Presidio Production Co is an independent oil and natural gas company engaged in oil and gas exploration and production, with operations concentrated across the Western Anadarko Basin of Texas, Oklahoma, and Kansas. It oeprates in one reportable segment, which is engaged in the acquisition, development, exploration, and production of oil and natural gas properties. It derives its revenue from customers through the sale of oil, natural gas, and NGLs as well as other immaterial service contracts in United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.